Supplementary Table S3. Progression-free survival in core plus OLE studies (continued-lanreotide patients) or core study only (placebo patients) across clinically-relevant and pre-specified subgroups defined according to baseline characteristics in the core study (ITT population)

	Number of events /patients		Median PFS [95% CI] (months)	
	LAN	PBO	LAN[a]	PBO[b]
Subgroup				
Tumour origin				
Midgut	13 / 33	23 / 40	42.8 [30.9, 68.0]	21.1 [17.0, NR]
Pancreas	22 / 42	33 / 49	29.7 [12.0, 32.4]	12.1 [9.4, 18.3]
Hindgut	5 / 11	2 / 3	31.0 [2.9, NR]	24.4 [12.0, 24.4]
Other/unknown	5 / 15	6 / 11	49.0 [32.8, NR]	15.0 [6.3, NR]
Tumour grade				
1	28 / 69	40 / 72	42.8 [31.0, NR]	18.3 [12.7, 24.0]
2	17 / 32	19 / 29	29.7 [16.6, 32.8]	12.1 [9.0, 18.0]
Hepatic tumour load				
≤25%	23 / 62	41 / 75	42.8 [31.0, NR]	21.1 [17.6, 24.4]
>25%	22 / 39	19 / 28	24.1 [9.3, 49.0]	9.4 [6.3, 12.0]
PD at core-study baseline				
Yes	3 / 4	3 / 5	3.1 [3.0, 3.2]	6.2 [3.0, NR]
No	42 / 97	61 / 98	37.1 [31.0, NR]	18.0 [12.7, 24.0]
Previous therapy for non-functioning NET				
Yes	11 / 16	9 / 16	29.7 [6.0, 31.2]	14.4 [6.0, NR]
No	34 / 85	55 / 87	42.8 [31.3, NR]	18.0 [12.1, 24.0]
Region				
US	5 / 16	9 / 14	NR	9.4 [9.0, NR]
Outside US	40 / 85	55 / 89	32.4 [29.7, 49.0]	18.0 [12.7, 24.0]

Data in months are approximated based on 4 weeks per month.

[a]Median PFS data for lanreotide Autogel are calculated from OLE study data appended to core study data for all patients randomly allocated to lanreotide treatment in the core study.

[b]Median PFS data for placebo are calculated from the core study data only as patients continuing into the OLE study switched to lanreotide treatment.

ITT, intention-to-treat; LAN, lanreotide; NET, neuroendocrine tumour; NR, not reached; PBO, placebo; PD, progressive disease; PFS, progression-free survival.